Vaxart Inc (VXRT) Kazanmak

Vaxart, Inc. is a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. The company is headquartered in South San Francisco, California and currently employs 65 full-time employees. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. The Company’s development programs include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), its first immune-oncology indication. The firm's platform technology employs a vector-based approach and consists of various components, such as vector, antigen, and adjuvant. A vector is a virus used as a carrier to deliver DNA coding for vaccine antigens and an adjuvant selected to activate the immune system. An antigen is a viral or bacterial protein that stimulates an immune response to the targeted pathogen.